{
    "id": 1390,
    "fullName": "KRAS amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "KRAS amplification indicates an increased number of copies of the KRAS gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3845,
        "geneSymbol": "KRAS",
        "terms": [
            "KRAS",
            "'C-K-RAS",
            "C-K-RAS",
            "c-Ki-ras",
            "c-Ki-ras2",
            "CFC2",
            "K-Ras",
            "K-Ras 2",
            "K-RAS2A",
            "K-RAS2B",
            "K-RAS4A",
            "K-RAS4B",
            "KI-RAS",
            "KRAS1",
            "KRAS2",
            "NS",
            "NS3",
            "OES",
            "RALD",
            "RASK2"
        ]
    },
    "variant": "amp",
    "createDate": "08/12/2014",
    "updateDate": "04/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4086,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In retrospective study of a Phase III trial, melanoma patients harboring KRAS amplification treated with a combination of Paraplatin (carboplatin), Taxol (paclitaxel), and Nexavar (sorafenib) demonstrated a greater overall survival when compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Nexavar (sorafenib) (PMID: 26307133).",
            "molecularProfile": {
                "id": 1413,
                "profileName": "KRAS amp"
            },
            "therapy": {
                "id": 3428,
                "therapyName": "Carboplatin + Paclitaxel + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4403,
                    "pubMedId": 26307133,
                    "title": "Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26307133"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2142,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells with amplification of PIK3CA and KRAS in culture (PMID: 22662154).",
            "molecularProfile": {
                "id": 5417,
                "profileName": "KRAS amp PIK3CA amp"
            },
            "therapy": {
                "id": 2619,
                "therapyName": "BEZ235 + PD98059",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 348,
                    "pubMedId": 22662154,
                    "title": "Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22662154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4475,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M and amplified KRAS were resistant to Tagrisso (osimertinib) treatment in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18232,
                "profileName": "EGFR exon 19 del EGFR T790M KRAS amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4474,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of EGFR T790M and amplified KRAS in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18232,
                "profileName": "EGFR exon 19 del EGFR T790M KRAS amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4500,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib increased Parp cleavage, and highly suppressed phosphorylated Erk in human non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and a gain in KRAS in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18232,
                "profileName": "EGFR exon 19 del EGFR T790M KRAS amp"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4480,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified KRAS in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18233,
                "profileName": "EGFR exon 19 del KRAS amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4481,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified KRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18233,
                "profileName": "EGFR exon 19 del KRAS amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16593,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after achieving stable disease for 24 weeks with Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment, KRAS amplification was identified as an acquired alteration at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 25925,
                "profileName": "BRAF V600E KRAS amp"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7684,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25925,
                "profileName": "BRAF V600E KRAS amp"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7683,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25925,
                "profileName": "BRAF V600E KRAS amp"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7685,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25925,
                "profileName": "BRAF V600E KRAS amp"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7686,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25925,
                "profileName": "BRAF V600E KRAS amp"
            },
            "therapy": {
                "id": 4544,
                "therapyName": "Dabrafenib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7625,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired KRAS amplification (PMID: 27312529).",
            "molecularProfile": {
                "id": 25925,
                "profileName": "BRAF V600E KRAS amp"
            },
            "therapy": {
                "id": 4525,
                "therapyName": "Cetuximab + Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11187,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and KRAS demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 28341788).",
            "molecularProfile": {
                "id": 27925,
                "profileName": "FGFR1 amp KRAS amp"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15585,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15559,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Xalkori (crizotinib) and Tykerb (lapatinib) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 3440,
                "therapyName": "Crizotinib + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15587,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15578,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Xalkori (crizotinib) and Linsitinib (OSI-906) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 7667,
                "therapyName": "Crizotinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15573,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Xalkori (crizotinib) and Alpelisib (BYL719) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 7666,
                "therapyName": "Alpelisib + Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15583,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Xalkori (crizotinib) and Iressa (gefitinib) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 7668,
                "therapyName": "Crizotinib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15500,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung carcinoma harboring a MET exon 14 splice site mutation demonstrated an initial response to Xalkori (crizotinib) for 4 months, but then developed resistance, and was found to have acquired KRAS amplification, which was also confirmed in patient-derived cells in culture (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15586,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15556,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Xalkori (crizotinib), Tykerb (lapatinib), and Linsitinib (OSI-906) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 7665,
                "therapyName": "Crizotinib + Lapatinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15535,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell carcinoma patient-derived cells with KRAS amplification and a MET exon 14 splice site mutation demonstrated some apoptotic activity and inhibition of proliferation in culture when treated with Aliqopa (copanlisib) (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 995,
                "therapyName": "Copanlisib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15517,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of Xalkori (crizotinib) and Mekinist (trametinib) in non-small cell lung carcinoma patient-derived cells with KRAS amplification and a MET exon 14 splice site mutation led to increased Pi3k/Akt signaling, did not result in apoptotic induction, and only minimally reduced cell viability compared to Xalkori (crizotinib) treatment alone in culture (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 4480,
                "therapyName": "Crizotinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19311,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, combination of Mekinist (trametinib) with Xalkori (crizotinib) treatment resulted in rapid loss of KRAS amplification and MET exon 14 skipping mutation in cfDNA analysis, but was poorly tolerated and the patient passed away before radiographic response assessment (PMID: 31548343).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 4480,
                "therapyName": "Crizotinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16918,
                    "pubMedId": 31548343,
                    "title": "Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31548343"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15529,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells with KRAS amplification and a MET exon 14 splice site mutation treated with the combination therapy of Aliqopa (copanlisib) and Xalkori (crizotinib) demonstrated apoptotic activity and inhibition of cell proliferation in culture, and in patient-derived xenograft models, showed greater tumor growth inhibition compared to Xalkori (crizotinib) treatment alone (90.2% vs 69.4%, respectively) (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 7662,
                "therapyName": "Copanlisib + Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15551,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Linsitinib (OSI-906) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15584,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474).",
            "molecularProfile": {
                "id": 31071,
                "profileName": "KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15503,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, two patients with non-small cell lung carcinoma each harboring a MET exon 14 splice site mutation initially responded to treatment with Xalkori (crizotinib), however, each patient developed resistance after 14 months and 2 months, and both were found to harbor amplification of KRAS and EGFR (PMID: 30072474).",
            "molecularProfile": {
                "id": 31072,
                "profileName": "EGFR amp KRAS amp MET del exon14"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13406,
                    "pubMedId": 30072474,
                    "title": "Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30072474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15703,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Tagrisso (osimertinib) and Selumetinib (AZD6244) treatment resulted in increased apoptosis and reduced proliferation in non-small cell lung cancer cells harboring EGFR E746_A750del, EGFR T790M, and KRAS amplification in culture (PMID: 30322949).",
            "molecularProfile": {
                "id": 31153,
                "profileName": "EGFR E746_A750del EGFR T790M KRAS amp"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13578,
                    "pubMedId": 30322949,
                    "title": "KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15694,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acquired KRAS amplification in a non-small cell lung cancer cell line harboring EGFR E746_A750del and EGFR T790M resulted in resistance to inhibition of EGFR pathway signaling and proliferation by Tagrisso (osimertinib) in culture, and resistance to tumor growth inhibition in xenograft models (PMID: 30322949).",
            "molecularProfile": {
                "id": 31153,
                "profileName": "EGFR E746_A750del EGFR T790M KRAS amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13578,
                    "pubMedId": 30322949,
                    "title": "KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15698,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Selumetinib (AZD6244) and Linsitinib (OSI-906) treatment resulted in more potent ERK and AKT inhibition, induction of apoptosis, and reduction of proliferation than Selumetinib (AZD6244) alone in non-small cell lung cancer cells harboring EGFR E746_A750del, EGFR T790M, and KRAS amplification in culture (PMID: 30322949).",
            "molecularProfile": {
                "id": 31153,
                "profileName": "EGFR E746_A750del EGFR T790M KRAS amp"
            },
            "therapy": {
                "id": 7683,
                "therapyName": "Linsitinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13578,
                    "pubMedId": 30322949,
                    "title": "KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15697,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRAS amplification conferred resistance to inhibition of EGFR pathway signaling and profileration, and induction of apoptosis by Rociletinib (CO-1686) in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 30322949).",
            "molecularProfile": {
                "id": 31153,
                "profileName": "EGFR E746_A750del EGFR T790M KRAS amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13578,
                    "pubMedId": 30322949,
                    "title": "KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15702,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Gilotrif (afatinib) and Selumetinib (AZD6244) treatment resulted in reduced proliferation, decreased EGFR, AKT, and ERK signaling, and induction of apoptosis in a non-small cell lung cancer cell line harboring EGFR E746_A750del, EGFR T790M, and KRAS amplification in culture relative to treatment with Gilotrif (afatinib) or Selumetinib (AZD6244) alone (PMID: 30322949).",
            "molecularProfile": {
                "id": 31153,
                "profileName": "EGFR E746_A750del EGFR T790M KRAS amp"
            },
            "therapy": {
                "id": 7684,
                "therapyName": "Afatinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13578,
                    "pubMedId": 30322949,
                    "title": "KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15696,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) treatment did not reduce proliferation of non-small cell lung cancer cells harboring EGFR E746_A750del, EGFR T790M, and KRAS amplification in culture (PMID: 30322949).",
            "molecularProfile": {
                "id": 31153,
                "profileName": "EGFR E746_A750del EGFR T790M KRAS amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13578,
                    "pubMedId": 30322949,
                    "title": "KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16590,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after achieving stable disease for 32 weeks with Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, KRAS and MET amplification were identified as acquired alterations at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 31707,
                "profileName": "BRAF V600E KRAS amp MET amp"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20350,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung cancer patient with KRAS amplification and MET D1010H demonstrated a partial response for 3.9 months when treated with Xalkori (crizotinib) (PMID: 32034073).",
            "molecularProfile": {
                "id": 35146,
                "profileName": "KRAS amp MET D1010H"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21306,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) decreased EGFR phosphorylation levels and inhibited growth of non-small cell lung cancer cells harboring EGFR L858R, KRAS G12S, and KRAS amplification in culture, and cells homozygous for EGFR L858R demonstrated enhanced treatment sensitivity compared to cells with one copy of EGFR L858R (PMID: 32130260).",
            "molecularProfile": {
                "id": 36195,
                "profileName": "EGFR L858R KRAS G12S KRAS amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18612,
                    "pubMedId": 32130260,
                    "title": "Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32130260"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21305,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) decreased EGFR phosphorylation levels and inhibited growth of non-small cell lung cancer cells harboring EGFR L858R, KRAS G12S, and KRAS amplification in culture, and cells homozygous for EGFR L858R demonstrated enhanced treatment sensitivity compared to cells with one copy of EGFR L858R (PMID: 32130260).",
            "molecularProfile": {
                "id": 36195,
                "profileName": "EGFR L858R KRAS G12S KRAS amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18612,
                    "pubMedId": 32130260,
                    "title": "Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32130260"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1413,
            "profileName": "KRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5417,
            "profileName": "KRAS amp PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18232,
            "profileName": "EGFR exon 19 del EGFR T790M KRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18233,
            "profileName": "EGFR exon 19 del KRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25925,
            "profileName": "BRAF V600E KRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27925,
            "profileName": "FGFR1 amp KRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28958,
            "profileName": "ERBB2 pos KRAS amp MET N375S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28963,
            "profileName": "ERBB2 pos KRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31071,
            "profileName": "KRAS amp MET del exon14",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31072,
            "profileName": "EGFR amp KRAS amp MET del exon14",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31153,
            "profileName": "EGFR E746_A750del EGFR T790M KRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31707,
            "profileName": "BRAF V600E KRAS amp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35146,
            "profileName": "KRAS amp MET D1010H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 36195,
            "profileName": "EGFR L858R KRAS G12S KRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}